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ABSTRACT
Objective: A clinical diagnosis of bile acid
malabsorption (BAM) can be confirmed using SeHCAT
(tauroselcholic (75selenium) acid), a radiolabelled
synthetic bile acid. However, while BAM can be the
cause of chronic diarrhoea, it is often overlooked as a
potential diagnosis. Therefore, we investigated the use
of SeHCAT for diagnosis of BAM in UK hospitals.
Design: A multicentre survey was conducted
capturing centre and patient-level information detailing
patient care-pathways, clinical history, SeHCAT results,
treatment with bile acid sequestrants (BAS), and
follow-up in clinics. Eligible data from 38 centres and
1036 patients were entered into a validated
management system.
Results: SeHCAT protocol varied between centres,
with no standardised patient positioning, and differing
referral systems. Surveyed patients had a mean age of
50 years and predominantly women (65%). The mean
SeHCAT retention score for all patients was 19% (95%
CI 17.8% to 20.3%). However, this differed with
suspected BAM type: type 1: 9% (95% CI 6.3% to
11.4%), type 2: 21% (95% CI 19.2% to 23.0%) and
type 3: 22% (95% CI 19.6% to 24.2%). Centre-defined
‘abnormal’ and ‘borderline’ results represented over
50% of the survey population. BAS treatment was
prescribed to only 73% of patients with abnormal
results.
Conclusions: The study identified a lack of consistent
cut-off/threshold values, with differing centre criteria
for defining an ‘abnormal’ SeHCAT result. BAS
prescription was not related in a simple way to the
SeHCAT result, nor to the centre-defined result,
highlighting a lack of clear patient care-pathways. There
is a clear need for a future diagnostic accuracy study
and a better understanding of optimal management
pathways.
INTRODUCTION
Chronic diarrhoea is a commonly cited
reason for referrals to secondary and tertiary
care gastroenterology departments.1 2
Patients who present with chronic diarrhoea
often undergo a multitude of investigations,
which do not necessarily result in a
Summary box
What is already known about this subject?
▸ Bile acid malabsorption (BAM) is an established
cause of chronic diarrhoea and results in signifi-
cantly adverse quality of life for affected individuals.
▸ Diagnosis of BAM can be confirmed using
SeHCAT (tauroselcholic (75selenium) acid), a
radiolabelled synthetic bile acid. However, this
diagnostic tool is not consistently applied in
National Health Service (NHS) centres in the UK.
▸ Patients diagnosed with BAM can benefit from
the prescription of bile acid sequestrants (BAS);
however, there is known poor patient-reported
adherence with BAS treatment.
What are the new findings?
▸ There was a high level of heterogeneity in prac-
tice, with no standardised protocol, and no con-
sistently defined diagnostic threshold values of
SeHCAT retention.
▸ Suspected BAM type 1 patients had the highest
proportion of centre-defined abnormal results.
▸ Prescription of BAS was inconsistent across
patient groups, with notable numbers of patients
with low SeHCAT retention or centre-defined
‘abnormal’ results apparently not receiving BAS.
▸ The majority of patients who were prescribed
BAS reported improvement in clinical symptoms
of diarrhoea severity, pain, urgency or bloating,
highlighting the importance of identifying
patients who may benefit from BAS.
▸ Colesevelam is frequently prescribed as treat-
ment for BAM, although not licensed for this
purpose in the UK.
How might it impact on clinical practice in
the foreseeable future?
▸ Participating centres varied in their interpretation
of SeHCAT results with various cut-off/threshold
values. As this impacts on subsequent patient
treatment, we strongly recommend that a standar-
dised threshold value be established for the UK.
▸ The survey brings attention to the variable pre-
scription of BAS without clear patient care path-
ways, which needs to be addressed at a
national level.
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diagnosis. As the prevalence of chronic diarrhoea is esti-
mated to be 4–5% of adult Western populations, this
places a signiﬁcant cost burden on health systems such
as the National Health Service (NHS), as well as impact-
ing detrimentally on the quality of life of affected
patients.3–5 Bile acid malabsorption (BAM) is a frequent
cause of chronic diarrhoea.
Owing to lack of clinician awareness or access to
appropriate investigations, BAM may be overlooked and
patients left with incorrect diagnoses such as diarrhoea-
predominant irritable bowel syndrome (IBS-D).4–9
Furthermore, robust data on the prevalence of primary
and secondary BAM do not exist.
BAM is categorised into three types: type 1 is deﬁned
as BAM resulting from ileal resection or ileal inﬂamma-
tion (eg, in Crohn’s disease), type 2 is deﬁned as
primary or idiopathic and type 3 is deﬁned as secondary
to, or associated with, various gastrointestinal diseases or
conditions such as IBS, postcholecystectomy, chronic
pancreatitis, coeliac disease and diabetes mellitus.4 7 10
With recent key discoveries about the underlying patho-
physiology, this condition is increasingly (and more
accurately) also termed bile acid diarrhoea (BAD) as
true malabsorption is not always present, especially in
type 2.11
Conﬁrmation of a clinical diagnosis of BAM can be
made using SeHCAT (tauroselcholic (75selenium) acid),
a radiolabelled synthetic bile acid.1 3 12 13 The SeHCAT
test was introduced in the UK in 1981; however, it is
underutilised in the UK owing to various factors, such as
the lack of guidance on its role as a diagnostic tool, and
the practice among some clinicians of diagnosing BAM
(or BAD) by trial of bile acid sequestrant (BAS) treat-
ment (without the use of SeHCAT) among those with
chronic diarrhoea.3 11 However, there is no evidence
base for this practice. Furthermore, SeHCAT is not
licensed in many countries, for example the USA.14
The SeHCAT test involves measuring the retention of
radioactivity in the patient following administration of a
capsule containing SeHCAT.3 15 The patient is scanned
1–3 hours after taking the capsule, and this is repeated
(ideally) after 7 days to measure retention of the radiola-
belled bile acid. Low SeHCAT retention at day 7 repre-
sents an abnormal result and, therefore, a positive
diagnosis of BAM. There is no set cut-off threshold
established for the UK, although retention values of
<5% (or up to <10% or <15%) are generally considered
to be abnormal.3 4 SeHCAT results are occasionally used
to grade the severity of BAM, for example <5% retention
indicative of arbitrarily ‘severe’ BAM, between 5% and
10% retention as ‘moderate’ BAM and between 10%
and 15% retention as ‘mild’ BAM.3 However, these sever-
ity grades, much like the cut-off thresholds, are not stan-
dardised or validated.
Patients with a conﬁrmed or suspected clinical
diagnosis of BAM may be offered treatment with
BASs.2–4 7 12 13 16–18 BAS treatments such as colestyra-
mine and colestipol may be empirically offered in the
UK to patients with chronic diarrhoea as a trial of treat-
ment for suspected BAM. These treatments are known
to have poor adherence due to their unpleasant taste
and texture,5 14 19 and response rates can vary depend-
ing on the patient population.4 Constipation and other
gastrointestinal side effects are commonly reported.10 19 20
A newer BAS treatment, colesevalam, is available in
tablet form, avoiding the unpleasant taste and texture,
which may result in higher adherence in comparison to
the other BAS that come in a granule formulation sus-
pended as a resin in water.19 21 However, colesevalam,
although promoted as an alternative BAS7 16 22–24
because it may be more effective in binding to bile
acids, is not licensed in the UK for treatment of
BAM.14 21
There is also evidence that response to BAS treatment
is related to the result of the SeHCAT test,1 7 10 12 25 26
with authors suggesting that BAS prescription should be
targeted to certain patient populations depending on
their SeHCAT-informed BAM diagnosis.
The UK National Institute for Health and Care
Excellence (NICE) published Diagnostic Guidance
(DG7)3 on SeHCAT for the investigation of diarrhoea
caused by BAM in people diagnosed with IBS-D or
Crohn’s disease without ileal resection. DG7 concluded
that there were potential patient and system beneﬁts
from using SeHCAT for the diagnosis of BAM. However,
the guidance went on to note that insufﬁcient evidence
existed to determine whether or not SeHCAT was a cost-
effective diagnostic option, and, therefore, a programme
of research was recommended.
Kings Technology Evaluation Centre (KiTEC), an
External Assessment Centre funded by NICE, was
commissioned to address the research questions in DG7
through a series of multidisciplinary studies: a retro-
spective audit, a prospective survey and a diagnostic
accuracy study.13 27–29 The prospective survey is pre-
sented here (the second of the study series) and aimed
to describe the day-to-day practice associated with the
clinical indications for referring patients for a SeHCAT
test in NHS centres. These data will inform future diag-
nostic and treatment pathways by providing the neces-
sary background information for the design of the ﬁnal
study in this series, which will assess speciﬁcally the
research questions posed in DG7.
More speciﬁcally, the service evaluation reported in
this paper aimed to characterise the variability in centre
practice and procedures, patient clinical history,
SeHCAT test results and treatment including BAS pre-
scriptions rates.
METHODS
A prospective survey was designed to capture relevant
data (including patient referral, symptom history,
SeHCAT scan technique, results and clinical follow-up)
related to the SeHCAT test performed on each eligible
patient. A pilot phase ran during February and March
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2014. The full prospective survey was launched in
March 2014, and patient recruitment was open from
March 2014 until August 2015. The survey was devel-
oped in consultation with members of a Clinical
Advisory Board (CAB) (see appendix).
Inclusion criteria
NHS centres were recruited through a variety of
methods, including direct emails to all centres listed on
a SeHCAT database provided by the British Nuclear
Medicine Society (BNMS), based on the work of Smith
and Perkins,30 contact with members of the CAB and
notices on the BNMS and British Society of
Gastroenterology (BSG) websites.31 32 Formal commit-
ments to participate were obtained from a consultant
gastroenterologist and the Nuclear Medicine depart-
ment at each centre. A total of 40 centres registered to
participate in the survey (see Acknowledgments section
for the participating centres).
Any patient referred for a SeHCAT test with a clinical
suspicion of BAM because of chronic diarrhoea without
a known cause was eligible for inclusion in the prospect-
ive survey. It was a requirement that the patient had at
least one of their SeHCAT scans (day 1 or day 7) during
the survey period, even if they were referred for the test
prior to the start of the survey. Formal ethical approval
and individual patient consent were not required for the
survey, as it was an evaluation of practice and did not
require any change to normal clinical practice.
Data collection and testing
Survey data were entered by NHS staff (such as gastro-
enterologist or nuclear medicine technicians) into a vali-
dated data management system, MedSciNet. Data were
collected either during patient consultations (eg, patient
symptoms) or from patient notes (eg, SeHCAT results).
A pilot survey was conducted in ﬁve NHS centres (see
Acknowledgments section) by collecting data for a
sample of SeHCAT procedures. The feasibility, accept-
ability and availability of the tool to capture the relevant
data were also tested. The pilot ran for 3 weeks (17
February to 7 March 2014). Feedback was collected, and
this was used to optimise the proposed data collection
strategy. Data collected in the pilot survey were deemed
to be of sufﬁcient quality to be added to the full pro-
spective survey.
Statistical analysis
Data analysis was descriptive with appropriate summary
statistics (means, medians, SDs, percentages, 95% CIs)
and performed using SPSS (V.21) and Microsoft Excel
(V.14).
RESULTS
Centre overview
In total, 38 centres agreed to participate and contribu-
ted data to the SeHCAT survey (see online
supplementary ﬁgure S1). The total number of SeHCAT
investigations undertaken by the participating centres in
the 6 months of the survey was 1070.
Participating centres had been providing a routine
SeHCAT service for a median of 13 years (range: 1–
33 years). The majority of centres (68%, n=26/38)
reported providing a service for 10+ years while 29%
(n=11/38) of centres had been providing the service for
20+ years. Thirteen per cent of centres (n=5/38)
reported providing a routine SeHCAT service for
<5 years.
Centre-deﬁned threshold values for the SeHCAT
retention results were reported by 32 centres, and fol-
lowed two main patterns, using either three categories
(normal, borderline or abnormal, n=25) or four cat-
egories (normal, mild, moderate or severe/abnormal,
n=7). Threshold values for ‘normal’ ranged from
≥10% to ≥20% retention. The majority of centres
(69%, n=22/32) reported a ‘normal’ cut-off of ≥15%.
Threshold values for ‘borderline’ ranged from a lower
value of 5–15% to a higher value of 10–19%. Threshold
values for ‘abnormal’ were all recorded from 0% reten-
tion with an upper limit between 4% and 14%. Centres
(n=7/32), which reported across four categories
(normal, mild, moderate and severe/abnormal), were
very similar in cut-off values. All but one of these
centres reported the following: normal (≥15%), mild
(10–14.9%), moderate (5–9.9%) and severe/abnormal
(0–4.9%).
Follow-up in clinics was not routinely conducted in
24% (n=9/38) of centres, with a common statement that
the ﬁnal report is usually sent back to the referrer (ie,
internal consultant or external centre). The main
source of SeHCAT test funding for centres was from out-
patient appointments (74%, n=28/38), and 34% (n=13/
38) of centres reported that the cost of SeHCAT was
included in bundle of care.
In 42% of centres (n=16/38), the Se-75 high-energy
peak (264 keV/279 keV approximately) window was used
during the ﬁrst scan, while 52% of centres (n=20/38)
responded that they used a different approach. Of
these, n=11/20 centres reported using the Se-75 high-
energy peak (∼264 keV/279 keV) and the Se-75 low
energy peak (∼137 keV) windows. Centres also elabo-
rated on the use of SeHCATequipment and patient posi-
tioning procedures (see table 1).
Patient clinical information
A total of 1036 eligible patients (n=34 patients did not
meet inclusion criteria) were entered into the SeHCAT
survey database, each of whom had a SeHCAT
scan during the period of the survey (see table 2
for their demographic characteristics and online
supplementary ﬁgure 1 for patient recruitment).
The suspected BAM type based on clinical indications
was provided for 752 patients, prior to undertaking the
SeHCAT test. Type 1 was the smallest group (14%,
n=107/752), followed by type 3 (41%, n=310/752) and
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then type 2 (45%, n=335/752). The majority of
patients had undergone multiple diagnostic tests since
symptoms began, such as blood tests, stool tests and
colonoscopies.
Details of patients’ clinical symptoms were collected
prior to the ﬁrst SeHCAT scan (see online
supplementary table S1). Patients across all suspected
BAM types reported high levels of diarrhoea (three or
more times per day), bloating and nocturnal diarrhoea.
Using the Bristol Stool Chart as a guide, 92% of patients
(n=555/603) reported that their main type of stool pro-
duced in a typical week was diarrhoeal in nature (stool
types 5, 6 or 7).
First and second SeHCAT scans
Each patient received an initial scan following administra-
tion of the SeHCAT capsule, and a follow-up scan usually
scheduled for 1 week later. The time between the ﬁrst and
second scan was exactly 7 days for 99% of patients
(n=1007/1021). The time between administration of the
SeHCATcapsule and initial scan ranged from 8 to 339 min,
with a mean of 187 min (SD: 50). For the majority of
patients, there was no modiﬁcation to food or drink prior
to the scans (ﬁrst scan: 66%, second scan: 81%). The next
largest categories were fasting overnight (before ﬁrst scan)
and having a light breakfast (before second scan). For
most patients (almost 90% for both scans), there was no
modiﬁcation of medication prior to the scans.
The distance between the patient’s stomach or back
and the detector was highly variable for both scans. This
is likely to reﬂect the difference in position of the patient
during the scan (eg, prone vs sitting). The mean esti-
mated time required to perform each scan was 9.3 min
(SD: 5.3), and the duration ranged from 1.7 to 30 min.
SeHCAT results
SeHCAT retention scores were provided for 824 patients
of the 1036 eligible patients. The retention scores were
positively skewed with a peak towards lower retention
and an overall mean retention score of 19% (95% CI
17.8% to 20.3%, median=15%). The percentage
SeHCAT retention differed with suspected BAM type:
type 1 had a mean retention of 9% (95% CI 6.3% to
11.4%), the mean for type 2 was 21% (95% CI 19.2% to
23.0%), and the mean for type 3 was 22% (95% CI
19.6% to 24.2%) (ﬁgure 1).
Fifty per cent of patients (n=412/824) had a SeHCAT
retention score of <15%, and 24% (n=196/824) had a
score of <5%. The breakdown of SeHCAT retention scores
in 5% bands by the BAM type is shown in table 3. Around
60% of suspected BAM type 1 patients had a SeHCAT
retention of <5%, while a similar percentage of suspected
BAM types 2 and 3 had retentions of 15% or more.
Forty-three per cent (n=358/828) of patients had a
centre-deﬁned ‘abnormal’ result, with 7.5% (n=62/828)
deﬁned as ‘borderline’ and 47% (n=388/828) deﬁned as
‘normal’. Suspected BAM type 1 had the lowest overall
‘normal’ result of 21% (n=22/107), whereas suspected
BAM types 2 and 3 had a higher proportion of ‘normal’
results, with 54% and 53%, respectively (n=177/329 and
n=162/308). Of patients with <5% SeHCAT retention,
96% (n=185/193) had a centre-deﬁned ‘abnormal’
result, as did 91% (n=110/121) of those with a SeHCAT
retention of 5% to <10% (ﬁgure 2). For patients with a
SeHCAT retention of 15% or more, 92% (n=381/412)
had a centre-deﬁned ‘normal’ result (ﬁgure 2). Those
patients whose SeHCAT retention score lay in the range
10% to <15% were divided between the ‘abnormal’
(59%, n=56/95) and ‘borderline’ (35%, n=33/95)
centre-deﬁned categories.
Treatment and follow-up
Overall, BAS was reported as being prescribed to 37% of
patients post-SeHCAT (n=265/717). Prescription of BAS
was most frequent among suspected BAM type 1 patients
Table 1 SeHCAT equipment and patient positioning
procedures
SeHCAT procedures
Centres
(n=38)
System for scanning/measuring SeHCAT retention
Dual head gamma camera (uncollimated) 32 (84%)
Single head gamma camera (uncollimated) 3 (8%)
Whole body counter 1 (3%)
Probe system 2 (5%)
Patient position during first scan
Prone/supine on a gamma camera scanning
couch
24 (63%)
Sitting or standing distant from a gamma
camera
8 (21%)
Prone/supine on floor/mattress/low bed 5 (13%)
Whole body counter 1 (3%)
Patient set up recorded at day 0 for reproduction at day 7
Yes 27 (71%)
Views acquired for patient during first scan
Two abdominal views (AP+PA) sequentially 16 (42%)
Two abdominal views (AO+PA)
simultaneously
13 (34%)
AP+PA simultaneously in wholebody mode 6 (16%)
‘Two abdominal views (AP+PA) sequentially’
or ‘Two abdominal views (AO+PA)
simultaneously’
2 (5%)
Other 1 (3%)
Count a standard to compensate for detector drift and/or
Se-75 decay
Yes 6 (16%)
Use standard capsule acquisition as quality control
measurement*
Yes 7 (18%)
Perform more than one background reading where there is
a batch of patients*
Yes 22 (58%)
The data are presented as the total number (%) unless specified.
Missing data are not reported in the table.
*One centre did not respond.
AO, aorta (abdominal); AP, anteroposterior; PA, posteroanterior;
SeHCAT, tauroselcholic (75selenium) acid.
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(56%, n=55/98) compared to BAM types 2 and 3 (34%
and 33%, respectively). Patients with a SeHCAT reten-
tion of <5% or between 5% and 10% were prescribed
BAS in 72% (n=123/172) and 76% (n=78/102) of cases,
respectively. BAS was prescribed to 73% (n=117/161) of
patients with a centre-deﬁned abnormal result.
Table 2 Demographics and background information
Patient overview Overall
Demographics (n=1036)
Age: range: 6–89 mean (SD) 49.7 (17)
Gender: male 364 (35%)
Ethnicity
White 801 (77%)
Mixed 6 (0.6%)
Asian or Asian British 36 (34%)
Black or Black British 11 (1.1%)
Chinese or other ethnic group 10 (1.0%)
Not stated 172 (17%)
Suspected BAM type (n=752)
BAM type 1 107 (14%)
Crohn’s disease (yes) 85
Ileal damage (yes) 46
Radiotherapy suspected of causing BAM type 1 1
BAM type 2 335 (45%)
BAM type 3 310 (41%)
IBS diagnosed (yes) 78
IBS suspected 93
Predominant IBS subtype among IBS diagnosed/suspected patients (n=171)
Constipation (IBS-C) 2
Diarrhoea (IBS-D) 141
Alternating (IBS-A) 22
Postcholecystectomy 98
Diabetes 35
Coeliac disease 14
Microscopic colitis 13
Collagenous colitis 5
Lymphocytic colitis 5
Patient is taking medications that may influence the SeHCAT test (n=732)
Yes 117 (16%)
Type of medication
Bile acid sequestrants 9
Powerful anti-inflammatory drugs 21
Drugs affecting bowel motility (eg, opiates) 78
Other* 12
Lengths of time patients have had diarrhoea (or related symptoms) (n=736)
Less than 12 months 180 (24%)
1–3 years 235 (32%)
3–5 years 106 (14%)
Longer than 5 years 181 (25%)
Not known 34 (5%)
Diagnostic tests that have been performed since beginning of symptoms
Suspected BAM type BAM type 1 (n=107) BAM type 2 (n=335) BAM type 3 (n=310)
Blood tests 98 305 274
Stool tests 80 218 185
Colonoscopy 90 255 234
Flexible sigmoidoscopy 12 43 41
Oesphagogastroduodenoscopy 14 68 104
Complex imaging (eg, CT, MRI) 53 86 73
Other 3 11 16
*Other types of medication listed include the following: codeine, loperamide, immodium, L-thyroxine, infliximab, ammitryptiline, aspirin,
ibuprofen, colesevalam, metronidazole.
BAM, bile acid malabsorption; IBS, irritable bowel syndrome; SeHCAT, tauroselcholic (75selenium) acid.
Summers JA, Peacock J, Coker B, et al. BMJ Open Gastro 2016;3:e000091. doi:10.1136/bmjgast-2016-000091 5
Open Access
The SeHCAT survey captured additional outpatient
follow-up information for two patient groups: 140
patients who were prescribed BAS treatment, and 200
patients who were not prescribed BAS, regardless of
their SeHCAT result.
Among patients followed-up, colestyramine was the
main type of BAS prescribed (70%, n=96/138), and this
was the favoured treatment regardless of suspected BAM
type or SeHCAT retention result (see online
supplementary table S2). A second line of BAS treat-
ment was prescribed for 18% (n=22/119) of patients.
Patient-reported adherence to BAS prescription was
76% (n=77/101) for all patients followed-up. Among
those prescribed BAS, 21 reported side effects from the
BAS treatment.
A reduction in the severity of diarrhoea symptoms
(moderate to complete cessation) was reported by 71%
(n=63/89) of patients, since beginning BAS treatment
(see online supplementary table S3). Reduction (moder-
ate to complete cessation) in the severity of several symp-
toms was reported by patients after the start of BAS
treatment: reduced pain associated with symptoms by
42% (n=28/53); reduced frequency of urgency asso-
ciated with symptoms for 69% (n=50/73); and reduced
severity of bloating for 46% (n=23/49).
Patients described their experience with BAS, with
some reporting further gastrointestinal symptoms:
a lot of improvement but not total cure
very good, a vast improvement
feeling bloating and windy
not nice to take due to taste and bloating
difﬁcult to take granules
did not like Colestyramine at all. Tolerated Colesevalam
better.
Among followed-up patients not prescribed BAS
(n=200), the majority reported no change post-SeHCAT
in the severity of diarrhoea symptoms (69%, n=108/
157), severity of pain (82%, n=104/127), frequency of
urgency (81%, n=102/124) and severity of bloating
(87%, 107/123) (supplementary table 3).
Adverse events
Adverse events were only reported by one centre in the
survey. Twenty-eight patients had a single adverse event,
and ﬁve patients had two adverse events, resulting in 38
adverse events in total. Some of the adverse events were
recorded as being a result (n=5/38) or likely/possibly
result (n=20/38) from the SeHCAT test itself. For the
eight patients who reported severe side effects, these
were described in free text ﬁelds as:
Bloated, rough back of throat, sweaty/sick
Bloating (but after a meal)
Diarrhoea, sickness & stomach cramps
Vomiting, bad stomach pain.
Figure 1 SeHCAT retention by suspected BAM types: box
and whisker plots. Circles represent outliers. BAM, bile acid
malabsorption; SeHCAT, tauroselcholic (75selenium) acid.
Table 3 SeHCAT results and centre-defined results by suspected BAM type
Suspected BAM type
BAM
type 1 (n=107)
BAM
type 2 (n=335)
BAM
type 3 (n=310) Overall
SeHCAT % test retention, n (%)
<5% 63 (59%) 47 (14%) 61 (20%) 196 (24%)
5% to <10% 16 (15%) 46 (14%) 44 (15%) 121 (15%)
10% to <15% 6 (5.6%) 44 (13%) 31 (10%) 95 (12%)
15%+ 22 (21%) 189 (58%) 170 (56%) 412 (50%)
Total 107 326 306 824
Centre-defined results, n (%)
Normal 22 (21%) 177 (54%) 162 (53%) 388 (47%)
Borderline 5 (4.7%) 20 (6.0%) 26 (8.4%) 62 (7.5%)
Abnormal 78 (73%) 118 (36%) 117 (38%) 358 (43%)
Other* 2 (1.9%) 14 (4.3%) 3 (1.0%) 20 (2.4%)
Total 107 329 308 828
*Other often described as ‘severe BAM’ or ‘moderate BAM’.
BAM, bile acid malabsorption; SeHCAT, tauroselcholic (75selenium) acid.
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DISCUSSION
The main aim of this prospective survey was to describe
the day-to-day practice associated with the clinical indica-
tions for referring patients for a SeHCAT test, and their
subsequent management, in order to inform future
diagnostic and treatment pathways. Recruitment
exceeded expectations for the number of centres (38
centres contributed data) and eligible patients
(n=1036). Centres described their procedures for refer-
rals, funding and equipment related to SeHCAT.
This study was designed as a service evaluation, and so
it was not possible to undertake additional patient
follow-up where this was not normal clinical practice.
Hence, there were no follow-up data for 24% of centres
that did not routinely follow-up patients themselves.
One key ﬁnding was that centres varied widely in their
interpretation of SeHCAT results with differing cut-off/
threshold values. This is consistent with previous ﬁnd-
ings.3–5 For example out of 32 centres, 25 reported
using three categories of ‘normal’, ‘borderline’ and
‘abnormal’ while seven used four categories of ‘normal’,
‘mild’, ‘moderate’ and ‘severe/abnormal’. Among the
former, over 90% of SeHCAT results showing <10%
retention had been graded as ‘abnormal’ by centres,
and similarly over 90% of SeHCAT results of 15% of
more were graded as ‘normal’. Notably, patients with a
retention score between 10% and 15% were classiﬁed
differently by different centres, with 59% deﬁned as
abnormal and 35% deﬁned as borderline. These incon-
sistent threshold values may be impacting on subsequent
patient treatment and, in common with previous
authors,4 we therefore recommend that a standardised
threshold value be established for the UK. This will
require a prospective diagnostic accuracy study, includ-
ing consistent and standardised methodologies between
participating centres collected alongside prospective
data about therapeutic responses to BAS in order to set
a validated and clinically useful threshold value or
range. Parallel evaluation of other markers of bile acid
handling such as faecal bile acids would also be valuable.
Such a study has already been designed with a detailed
protocol available.13
The mean overall SeHCAT retention score for patients
was 19%, and this differed depending on the suspected
BAM type, with suspected type 1 having the lowest mean
retention of 9%. Similarly, 79% of patients with sus-
pected BAM type 1 had SeHCAT retention of <15%,
compared with 42% and 45% for patients with types 2
and 3, respectively. This is consistent with expectations,
as lower retention scores should certainly be seen in
patients who have terminal ileal disease or resection, as
per previous studies.1 17 The fact that 21% of type 1
patients have SeHCAT scores of over 15% suggests that
empirical trials of therapy in this group, bypassing the
SeHCAT test altogether, would be a suboptimal
approach. For the other BAM types (2 and 3), where
the majority of the SeHCAT results are over 15%, the
test has potential utility in targeting treatment or further
investigation.
Aspects of the SeHCAT scans themselves were cap-
tured at an individual patient level. A consistent ﬁnding
was that almost all patients underwent their second
SeHCAT scan 7 days after the ﬁrst. Prior to the SeHCAT
scans, 16% of patients (n=117/732) reported taking
medication that might have inﬂuenced the SeHCAT test.
A further study would need to address this potentially
confounding factor. Current guidelines suggest that in
patients over 45 years of age, colonoscopies are under-
taken before undergoing a SeHCAT test.2 3 However,
this survey found that among 45+ year olds, 29%
(n=101/351) reported no colonoscopy (since symptoms
began) prior to SeHCAT, suggesting that the guidelines
Figure 2 SeHCAT retention
result by centre-defined result.
*Other often described as ‘severe
BAM’ or ‘moderate BAM’. BAM,
bile acid malabsorption; SeHCAT,
tauroselcholic (75selenium) acid.
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are not closely followed in the UK gastroenterology com-
munity, at least in centres with access to SeHCAT.
Overall, BAS was reported as being prescribed to just
over a third of patients, with the majority (70%) initially
prescribed colestyramine, reﬂecting the ﬁndings of a
similar study where colestryamine represented the most
commonly prescribed BAS treatment.18 Although colese-
velam is not licensed for use in the UK for BAM treat-
ment, 28% of patients prescribed BAS were speciﬁcally
prescribed colesevelam. Notably, BAS was not prescribed
for 27% of patients with a centre-deﬁned ‘abnormal’
result, nor to 24% of patients with a SeHCAT score of
<15%, highlighting an apparent inconsistency in how
the SeHCAT information is used within patient care
pathways across these NHS centres. It is not clear how
the SeHCAT retention score inﬂuences the decision to
prescribe BAS, or if this is determined by other clinical
factors or centre-speciﬁc guidelines.
A fundamental aim of the survey was to capture
follow-up information on patients who were either pre-
scribed BAS or not, regardless of the result of the
SeHCAT test. In total, 340 patients had follow-up infor-
mation entered into the database during the survey
period. Among 140 patients prescribed BAS, a majority
reported reduced clinical symptoms of diarrhoea sever-
ity, pain, urgency or bloating. The majority of the 200
patients who were not prescribed BAS reported no
change post-SeHCAT in clinical symptoms. A limitation
of the study is the high level of missing symptomatology
data among the followed-up patients. The numbers are
too small to fully interpret the relationship between
symptom improvement and SeHCAT retention or sus-
pected BAM type. Furthermore, the length of time for
which BAS prescriptions were continued could not be
ascertained.
One of the ﬁndings of this survey is the high level of
heterogeneity, both in centre practices and among the
patient population. Centres reported differing proce-
dures for carrying out SeHCAT scans and adopted differ-
ent SeHCAT retention cut-offs for determining an
abnormal result. The prescription of BAS seemed highly
variable and not simply linked to either the SeHCAT
retention value or the centre-deﬁned result. There was
also considerable variation in the use of a range of other
treatments post-SeHCAT, regardless of whether a patient
received a BAS prescription or not. The patient popula-
tion is heterogeneous by the nature of the three differ-
ent BAM types, particularly the range of secondary
conditions included within BAM type 3, and in their pre-
senting symptoms. Hence while the survey is large and
contains rich data, the ability to make meaningful com-
parisons between patient sub-groups is restricted by the
large number of confounding factors inherent in such
heterogeneity. This would support the case for a future
prospective, placebo-controlled trial of BAS, with clear
inclusion criteria and standardised protocols.
Another key ﬁnding was that many patients undergo
SeHCAT without prior colonoscopy, indicating that the
current BSG guidelines for investigating chronic diar-
rhoea3 are not adhered to, at least in centres with
access to SeHCAT. The guidelines, which would always
place colonoscopy before SeHCAT, may need reconsid-
eration as to the positioning of SeHCAT in the
pathway, but better primary evidence is required to
underpin this.
In summary, the survey has identiﬁed wide variations
in clinical practice in the interpretation of SeHCAT
results, and in management and follow-up, and limited
adherence to BSG guidelines. Coupled to variable access
to SeHCAT testing across the UK, these ﬁndings already
have signiﬁcant implications for the consistency and
equity with which patients with chronic unexplained
diarrhoea are assessed and managed in the UK NHS.
CONCLUSIONS
In this study, the current provision of SeHCAT to a
referred patient population with suspected BAM has
been characterised across 38 UK centres. The study has
provided valuable information on the distribution of
SeHCAT test results, on BAS prescription rates, and on
symptom improvement following treatment. The study
has conﬁrmed that a range of different criteria are used
by centres when deﬁning an ‘abnormal’ SeHCAT result.
BAS prescription was not simply related to the SeHCAT
result, nor to the centre-deﬁned result, but appears to be
inﬂuenced by other factors. The majority of patients
receiving BAS treatment showed an improvement in
symptoms.
The results of this survey have provided key informa-
tion to help optimise the design of a future diagnostic
accuracy study,13 to clarify the optimal classiﬁcation of
SeHCAT retention scores, and to enable the speciﬁc
research questions set out in the NICE DG7 guidance to
be addressed. Further research is also warranted to inves-
tigate the efﬁcacy of BAS according to BAM type,
SeHCAT retention and other clinical characteristics.
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